A safer Alzheimer’s drug

Alzheimer; News from the web:

In 2018, a research group led by David Holtzman, M.D., at Washington University in St. Louis developed an antibody drug in collaboration with Denali Therapeutics that showed promise as a potential Alzheimer’s disease therapy. Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab.

Read all about it HERE

Alzheimer’s impact on covid-19

Alzheimer; News from the web:

Our study provides a causal link between the Alzheimer’s disease risk factor ApoE4 and COVID-19 and explains why some (e.g., ApoE4 carriers) but not all COVID-19 patients exhibit neurological manifestations. Understanding how risk factors for neurodegenerative diseases impact COVID-19 susceptibility and severity will help us to better cope with COVID-19 and its potential long-term effects in different patient populations.”

Yanhong Shi, Ph.D., Director, Division of Stem Cell Biology, City of Hope and Study’s Co-Corresponding Author

Read all about it HERE

Spike in Alzheimer’s deaths

Alzheimer; News from the web:

Those living with Alzheimer’s or dementia have a higher risk of contracting coronavirus due to their age, but the pandemic has caused a leap in deaths for this population.

Read all about it HERE